实时图像引导前列腺癌消融放疗:TROG 15.01 SPARK试验结果
多中心前瞻性试验纳入48例前列腺癌患者,行千伏级实时监控(KIM)引导的SABR,总剂量36.25 Gy分5次。实时IGRT使无治疗出现前列腺CTV D98%剂量低于计划5%以上,且12个月患者报告结局无变化、无≥3级泌尿生殖或胃肠道毒性。
要点
- 实时IGRT下无治疗出现前列腺CTV D98%剂量较计划低5%以上。
- 无实时IGRT时13次治疗(5.5%)出现CTV D98%剂量较计划低5%以上。
- 12个月患者报告结局与基线无变化,无≥3级泌尿生殖或胃肠道毒性。
核心结论
- 实时图像引导放疗对前列腺癌SABR具有临床有效性。
研究设计与样本
- 多中心前瞻性试验纳入48例前列腺癌患者,行KIM引导SABR,总剂量36.25 Gy分5次。
主要发现
- 88%患者(42/48)和51%治疗(121/235)中至少一次治疗发生运动校正。
- 实时IGRT下无治疗出现前列腺CTV D98%剂量较计划低5%以上;无实时IGRT时13次治疗(5.5%)出现该情况。
- 实时IGRT下前列腺CTV D98%剂量平均更接近计划1.0%(范围-2.8%至20.3%)。
- 12个月患者报告结局与基线相比无变化,无≥3级泌尿生殖或胃肠道毒性。
关键数值与推荐
- 实时IGRT使前列腺CTV D98%剂量较计划低5%以上的治疗数为0,无实时IGRT时为13次(5.5%)。
临床怎么用
- 在前列腺癌SABR中采用KIM实时IGRT可减少靶区剂量偏差并维持低毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Kilovoltage intrafraction monitoring (KIM) is a novel software platform implemented on standard radiation therapy systems and enabling real-time image guided radiation therapy (IGRT). In a multi-institutional prospective trial, we investigated whether real-time IGRT improved the accuracy of the dose patients with prostate cancer received during radiation therapy. METHODS AND MATERIALS: Forty-eight patients with prostate cancer were treated with KIM-guided SABR with 36.25 Gy in 5 fractions. During KIM-guided treatment, the prostate motion was corrected for by either beam gating with couch shifts or multileaf collimator tracking. A dose reconstruction method was used to evaluate the dose delivered to the target and organs at risk with and without real-time IGRT. Primary outcome was the effect of real-time IGRT on dose distributions. Secondary outcomes included patient-reported outcomes and toxicity. RESULTS: Motion correction occurred in ≥1 treatment for 88% of patients (42 of 48) and 51% of treatments (121 of 235). With real-time IGRT, no treatments had prostate clinical target volume (CTV) D98% dose 5% less than planned. Without real-time IGRT, 13 treatments (5.5%) had prostate CTV D98% doses 5% less than planned. The prostate CTV D98% dose with real-time IGRT was closer to the plan by an average of 1.0% (range, -2.8% to 20.3%). Patient outcomes showed no change in the 12-month patient-reported outcomes compared with baseline and no grade ≥3 genitourinary or gastrointestinal toxicities. CONCLUSIONS: Real-time IGRT is clinically effective for prostate cancer SABR.
引用
- Keall P, Nguyen DT, O'Brien R, et al. Real-Time Image Guided Ablative Prostate Cancer Radiation Therapy: Results From the TROG 15.01 SPARK Trial. Int J Radiat Oncol Biol Phys. 2020. PMID: 32234553. doi:10.1016/j.ijrobp.2020.03.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。